Literature DB >> 15983393

Improved survival for patients with follicular lymphoma.

T Andrew Lister.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15983393     DOI： 10.1200/JCO.2005.03.911

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.

Authors:  Daphne de Jong; Ad Koster; Anton Hagenbeek; John Raemaekers; Dennis Veldhuizen; Sabien Heisterkamp; Jan Paul de Boer; Martine van Glabbeke
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

2.  Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma.

Authors:  Michael Herold; Christian W Scholz; Frank Rothmann; Carsten Hirt; Volker Lakner; Ralph Naumann
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-25       Impact factor: 4.553

3.  Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Authors:  Emmanuel Bachy; Roch Houot; Franck Morschhauser; Anne Sonet; Pauline Brice; Karim Belhadj; Guillaume Cartron; Bruno Audhuy; Christophe Fermé; Pierre Feugier; Catherine Sebban; Vincent Delwail; Hervé Maisonneuve; Steven Le Gouill; Sophie Lefort; Nicole Brousse; Charles Foussard; Gilles Salles
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.